IPO - Profile

Angion Biomedica Corp.

Health Care > Major Pharmaceuticals



We are a late-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Our goal is to transform the treatment paradigm for patients suffering from these potentially life-threatening conditions for which there are no approved medicines or where existing approved medicines have limitations. Our lead product candidate, ANG-3777, is a hepatocyte growth factor (HGF) mimetic that we are currently evaluating in multiple acute organ injuries and related indications, including acute kidney injury (AKI) and injuries to other More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$16.00 5,000,000 Positive High 33.32%

Offering Team

  • Legal counsel
  • Latham & Watkins LLP
  • Auditors
  • Moss Adams LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 04 Feb, 2021

Offer 05 Feb, 2021

Look Ahead

Lock Up Expiry Aug 05, 2021

IPO Terms

Offer Price $16.00
Offer Size 5M

Market Sentiments

Stock Price